All In Biotech

Drug Trial Radar · NCT01864746

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy "PENELOPEB"

Last checked: Nov 19, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,250

Actual

Start

Oct 30, 2013

Primary completion

Aug 24, 2020

Study completion Dec 21, 2020

Sponsor

Lead sponsor
GBG Forschungs GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer; AGO Study Group; NSABP Foundation Inc; Breast International Group
First posted
May 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The PENELOPEB study is designed to demonstrate that, in the background of standard anti-hormonal therapy, palbociclib provides superior invasive disease-free survival (iDFS) compared to placebo in pre- and postmenopausal women with HR-positive/HER2-normal early breast cancer at high risk of relapse after showing less than pathological complete response to neoadjuvant taxane- containing chemotherapy. Considering the high risk of recurrence in patients after neoadjuvant chemotherapy and a high CPS-EG score, palbociclib appears to be an attractive option with a favourable safety profile for these patients.

Conditions

  • Breast Cancer
  • Hormonreceptor Positive
  • Her2-normal
  • Postneoadjuvant Treatment With CDK 4/6 Inhibitor
  • CPS-EG Score

Interventions

  • Palbociclib PD-0332991Drug

    palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle

  • PlaceboDrug

    Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease Free Survival (iDFS) for Palbociclib vs. Placebo in Patients With High CPS-EG Score After Neoadjuvant Chemotherapy Receiving Standard Adjuvant Endocrine Therapy for HR-positive/HER2-normal Primary Breast Cancer.Time frame: From date of randomisation to data cut off: 24 August 2020 (approximately 6 years and 6 months)

Locations

11 sites in 11 countries. Site status is shown where the registry gives one.

  • NSABP Foundation

    Pittsburgh, Pennsylvania

  • Contact: Australia and New Zealand Breast Cancer Trials Group

    Newcastle, NSW 2310, Australia

  • Contact: Austrian Breast & Colorectal Cancer Study Group

    Vienna, Austria

  • Contact: NSABP Foundation

    Multiple Locations, Canada

  • Contact: UNICANCER

    Paris, France

  • Contact: German Breast Group

    Neu-Isenburg, Germany

  • Contact: Cancer Trials Ireland

    Dublin, Ireland

  • Contact: Japan Breast Cancer Research Group

    Tokyo, Japan

  • Contact: Korea Cancer Study Group

    Seoul, South Korea

  • GEICAM

    San Sebastián de los Reyes, Spain

  • Contact: Institute of Cancer Research

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.